https://www.selleckchem.com/pr....oducts/ap-3-a4-enobl
egy can be used in clinical treatment of IVD defect after discectomy. NCT03002207. NCT03002207. To circumvent possible systemic side effects, anti-angiogenic drugs targeting vascular endothelial growth factor (VEGF) for ocular neovascular diseases in adults are approved only for intravitreal administration. However, intravitreal injection itself can elicit injection-related adverse effects, and premature eyes of infants with retinopathy of prematurity (ROP) may be particularly susceptible to intravitreal injection. Therefore, a
Beğen
Yorum Yap
Paylaş
